Report Scope: This research report presents an in-depth analysis of the global cell therapy biomanufacturing market by product type, application and region. The report discusses the key inhibitors to the growth of cell therapy biomanufacturing.
New York, Feb. 15, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cell Therapy Biomanufacturing: Global Markets" - https://www.reportlinker.com/p06025094/?utm_source=GNW
The report discusses the role of participants in the supply chain from manufacturers to researchers.The report analyzes key companies operating in the global cell therapy biomanufacturing market.
In-depth patent analysis in the report will provide a look at the existing and coming technological trends.
In this report, the cell therapy biomanufacturing market is segmented by product type, application and region.Based on product type, the market is segmented into source of cells (T-cells, Dendritic cells, tumor cells and stem cells), and type of therapy (autologous cell therapies, allogeneic cell therapies).
The market by application is categorized into cardiovascular diseases, bone repair, neurological disorders, skeletal muscle repair, cancer and others. The market by region is segmented into North America, Europe, Asia-Pacific and ROW.
- 23 tables
- An overview of the global markets for cell therapy biomanufacturing
- Estimation of the market size and analyses of global market trends with data from 2019, 2020, and projections of compound annual growth rates (CAGRs) through 2025
- Assessment of market dynamics such as drivers, restraints, opportunities, and identification of growth inhibiting areas that affect the global market
- Detailed description of allogeneic (third party donor cells) and autologous (one’s own body cells) forms of cell therapy and analysis of its advantages and limitations
- Information on clinical trials of cell therapies; insights into regulatory scenarios and initiatives by government organization
- Evaluation of current market trends, market size, market forecast, and technological advancements within the industry
- Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies; and a relevant patent analysis
- Company profiles of major players of the industry, including Bristol-Myers Squibb Co., Caladrius Biosciences Inc., Lonza Group Ltd., Merck KGaA and Novartis AG
There are numerous indications that can be cured using cell therapies, and the number of therapeutic uses is expected to increase.Some of the indications under investigation for treatments using cell therapy are cerebral disorders such as Parkinson’s disease and Alzheimer’s disease, and cardiovascular disease.
Cardiovascular disease could be treated using cell therapies with the aim of restoring normal heart function.Moreover, many studies are underway to improve the safety and efficacy in the treatment of different malignancies.
Cell therapy could also be used to cure metabolic disorders such as diabetes mellitus type 1, where there is lack of insulin production in the patient. Researchers are also
trying to restore normal liver and kidney function by introducing modified cells of respective origins. Cell therapy is also a promising technique for the treatment of orthopedic, oncological, neurological and autoimmune diseases. The increase in the potential of cell therapies in the treatment of diseases associated with lungs using stem cell therapies is expected to be a major driver of the market’s growth. Another driver is improved understanding of the role of stem cells in inducing development of functional lung cells, from both embryonic stem cells (ESCs) and induced pluripotent stem (iPS) cells. Stem cell therapies provides further understanding of lung biology and repair after lung injury.
An increase in the incidence of cardiovascular diseases, rise in the demand for chimeric antigen receptor (CAR) T cell therapy, and further development of stem cell therapy approaches are driving the market’s growth.However, market restraints include the bottlenecks experienced by manufacturers during commercialization of cell therapies and the high costs associated with cell therapies.
The rise in the development of allogeneic cell therapy is expected to drive the market’s growth. Allogeneic cell therapy involves chemo radiotherapeutic conditioning therapy that is followed by transplantation of hematopoietic stem cells as well as lymphocytes isolated from allogeneic healthy donors for treatment
of various chronic diseases. (Allogeneic means from “one person to another,” vs. autologous, which means from “one person back to the same person after processing.”)
Hematopoietic stem cell transplantation is used for treatment of a variety of blood cancers and hematologic conditions. This transplantation is the most frequently used cell therapy procedure.
In this report, the cell therapy biomanufacturing market is segmented by product type, application and region.The market by application is classified into cardiovascular diseases, bone repair, neurological disorders, skeletal muscle repair and others.
The market by product time generated the highest revenue in 2019, and is anticipated to reach REDACTED by 2025, registering a compound annual growth rate (CAGR) of REDACTED. Skeletal/muscle repair generated the highest revenue among applications in 2019, and is anticipated to reach REDACTED by 2025, registering a CAGR of REDACTED. However, neurological diseases related to cell therapy biomanufacturing will grow at a faster rate, registering a CAGR of
REDACTED from 2020 to 2025. North America has the largest global cell therapy biomanufacturing market, whereas Asia-Pacific is the fastest-growing region.
Read the full report: https://www.reportlinker.com/p06025094/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001